Why the study?
Beyond a preference for cleaving RNA 3' of uridines, it was unknown whether Nsp15 has any additional substrate preferences.
Structural and biochemical characterization of SARS-CoV-2 Nsp15 reveals its RNA substrate preferences and critical active site residues, informing potential antiviral drug design.
Pre- and post-cleavage Nsp15-RNA structures extend coronavirus evasion mechanisms; leaves open inhibitor development.
Nsp15 is a uridine specific endoribonuclease that coronaviruses employ to cleave viral RNA and evade host immune defense systems. Previous structures of Nsp15 from across Coronaviridae revealed that Nsp15 assembles into a homo-hexamer and has a conserved active site similar to RNase A. Beyond a preference for cleaving RNA 3’ of uridines, it is unknown if Nsp15 has any additional substrate preferences. Here we used cryo-EM to capture structures of Nsp15 bound to RNA in pre- and post-cleavage states. The structures along with molecular dynamics and biochemical assays revealed critical residues involved in substrate specificity, nuclease activity, and oligomerization. Moreover, we determined how the sequence of the RNA substrate dictates cleavage and found that outside of polyU tracts, Nsp15 has a strong preference for purines 3’ of the cleaved uridine. This work advances our understanding of how Nsp15 recognizes and processes viral RNA and will aid in the development of new anti-viral therapeutics.
No takes yet. Share an insight, caveat, or question.
Frazier et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: